BIO’s Intellectual Property Counsel Committee is holding its Fall Conference and Committee Meeting on Oct. 20-22, 2008, at the Hard Rock Hotel at Universal Orlando, Orlando, Florida.
BIO’s semi-annual IP Counsels’ Committee Conference is an excellent opportunity for BIO members to hear, listen, and learn about current and projected topics related to biotechnology IP.
In the past, this has been a members’ only conference and closed to any type of media, social or otherwise. However, BIO has graciously agreed to allow me to attend and blog about the conference. Look for updates later this month.
Panelists include:
- John Doll, Commissioner for Patents, US Patent & Trademark Office
- Dr. Hans Sauer, Assoc. General Counsel for Intellectual Property, BIO
- Andy Brookes, VP & Chief IP Counsel, Biogen Idec
- Thomas Kelley, Patent Counsel, Monsanto Company
- Ken Dow, VP, Patents & Assistant Patent Counsel, Johnson & Johnson
- Maggie Shafmaster, Senior VP & Chief Patent Counsel, Genzyme
and many others.
Among topics to be discussed:
- Innovative mechanisms for PTO workload management
- US Patent and Trademark Office recent developments, rulemakings, and initiatives
- Implications of recent case law
- Updates on patents and IP around the world
- IP licensing and other contractual agreements
- Open innovation models
I hope to see you there. More information is available at the IPCC Conference website here [1].